Error Revenue and Competitors
Estimated Revenue & Valuation
- Error's estimated annual revenue is currently $1.7M per year.
- Error's estimated revenue per employee is $155,000
Employee Data
- Error has 11 Employees.
- Error grew their employee count by 0% last year.
Error Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $3.3M | 21 | -5% | N/A | N/A |
#3 | $1.4M | 9 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 25% | N/A | N/A |
#5 | $10.5M | 68 | 1% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4.8M | 31 | -11% | N/A | N/A |
#8 | $1.6M | 10 | 11% | N/A | N/A |
#9 | $7.4M | 48 | -11% | N/A | N/A |
#10 | $1.9M | 12 | -25% | N/A | N/A |
What Is Error?
Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and crosslinked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead programs based on 3DNA® nanotechnology. Our mission is to expand our collaborative partnerships and utilize our longstanding nanotechnology expertise to enhance the human condition through new 3DNA-based therapeutics. For us, this mission is much more than words on a page. We live this mission every day as we employ the unique characteristics of our flexible platform to support our continuing partnerships and to advance our own lead programs based on 3DNA® nanotechnology.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.9M | 13 | -38% | N/A |
#2 | $1.8M | 15 | 25% | N/A |
#3 | $2.2M | 22 | 47% | N/A |
#4 | $2.2M | 24 | -14% | N/A |
#5 | $3.7M | 25 | 4% | N/A |